Cellevate to announce major advances in yield and scalability of viral vaccine production at World Vaccine Congress

Cellevate to announce major advances in yield and scalability of viral vaccine production at World Vaccine Congress Europe with global launch of Cellevat3d® VAX nanofiber microcarriers

• >13-fold higher infectious viral vaccine titers in Vero cell cultures compared to industry-standard microcarriers
• 11.4-fold higher infectious enterovirus vaccine titers demonstrated in HEK293T cultures in an independent study conducted by Intravacc B.V. (CDMO, The Netherlands)
• Formation of homogeneous, high-density 3D spheroid cultures, supporting efficient virus propagation, high cell specific viral productivity and scale up
• 85% reduction in cost of production for viral vaccine processes compared to current industry-standard

LUND, Sweden, October 13, 2025 – Cellevate AB today announced the upcoming global launch at the World Vaccine Congress Europe in Amsterdam, October 14–16, 2025 of Cellevat3d® VAX nanofiber microcarriers for adherent cell-based viral vaccine production. Join our launch event and company presentation on October 16 at 12:30 in the Manufacturing Technologies track, where CTO Dr. Christel Fenge will present the outstanding performance data.

Adherent cell-based viral vaccine production traditionally relies on bead-based microcarriers, roller bottles, cell stacks, and fixed-bed bioreactors. While widely used, these methods are limited in scalability, cost-efficiency, and process robustness. The Cellevat3d® VAX product addresses these challenges by introducing sustainable, cellulose-derived nanofibers supporting the expansion of adherent cell cultures in conventional stirred-tank bioreactors. This breakthrough enables seamless process transfer, improved scalability, and significantly higher viral vaccine yields enhancing overall manufacturing efficiency. 

”With this new product launch, Cellevate demonstrates the versatility of its next-generation, nanofiber-based microcarrier platform across all areas of adherent cell cultivation. Breakthrough medicine requires breakthrough innovations in biomanufacturing and Cellevate will keep delivering on that paradigm,” commented Dr. Uwe Gottschalk, Chairman of the Board, Cellevate. 

“The key challenges in vaccine manufacturing are to bring new vaccines to the market faster and at lower production costs, only achievable through implementation of disruptive technologies. With more than 13-fold increase in viral vaccine titers, Cellevat3d® VAX nanofiber microcarriers have the potential to transform the way viral vaccines are manufactured and to accelerate vaccine development and patient access,” said Laura Chirica, CEO, Cellevate.

For more information about Cellevat3d® VAX nanofiber microcarriers, please visit: www.cellevate.com

For more information, please contact:

Laura Chirica, PhD

CEO Cellevate

Email: laura.chirica@cellevate.com

About Cellevate

Cellevate is a Swedish biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture solutions for cell and gene therapy and novel vaccines biomanufacturing. The core nanotechnology, Cellevat3d® is a sustainable, deeptech innovation for the biopharmaceutical industry. This platform allows industrial-scale production of a new category of nanofiber cell culture systems – with unparalleled surface area for cell growth, reproducibility, customization, and scalability, which ultimately lead to increased yield, productivity and process economy. Cellevat3d® nanofiber-based products are designed and validated as an integrated part of upstream bioprocessing solutions, from laboratory to large-scale production.

For more information, please visit www.cellevate.com.